Liminatus Pharma, Inc.
Liminatus Pharma, Inc. is a U.S.-based biopharmaceutical company that emerged from a 2025 business combination and recapitalization with Liminatus Pharma, LLC. Based on the disclosed filings, the company is still in an early development and public-company transition phase, with no revenue generated to date and operations centered on building and financing its future drug-development platform.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2024–2025
Liiketoiminta
Osuus liikevaihdostaPre-commercial pharmaceutical research and development activities aimed at creating future therapeutic products.
Use of company-owned IP to support eventual product development and monetization.
Business combination, PIPE financing, and public-company operating infrastructure.
Asiakkaat
The company does not yet appear to sell commercial products, so it currently has no meaningful end-customer revenue base. Its near-term stakeholders are investors, financing partners, and strategic counterparties supporting development and capitalization, while future customers would likely be healthcare providers, distributors, or patients depending on the eventual product portfolio.
Investors and financing partners supplying equity and debt capital to fund operations and the business combination.
Hospitals, physicians, pharmacies, or patients that could buy approved therapies if development succeeds.
Potential collaborators, licensors, or contract service providers supporting R&D and commercialization.
Strategia
The company’s immediate strategic focus is to complete the transition from a SPAC-style combination into a functioning public biopharma platform. Management’s disclosed priorities are to preserve liquidity, support development activities, and use the public listing and financing structure to fund future commercialization efforts.
The company needs a stable operating and reporting structure after the 2025 business combination.
The company has no revenue and depends on equity and debt financing to continue operations.
Future revenue depends almost entirely on successful product development and commercialization.
Maantiede
Liminatus Pharma is headquartered in the United States and operates as a Delaware-incorporated public company. The filings provided do not disclose country-level revenue or a meaningful operating footprint outside the U.S., and the company’s current exposure is primarily tied to U.S. capital markets and U.S. corporate governance requirements.
Riskit
Liminatus faces the classic risks of an early-stage biopharma company: no current revenue, dependence on external financing, and uncertainty around whether its intellectual property can become commercial products. The recent business combination also adds integration, public-company compliance, and dilution risk, while future development programs may face clinical, regulatory, and execution setbacks.
Management disclosed that the company did not generate revenue during the reported periods, so value creation depends on future product development.
Kohdistuu: Entire business model
Operations have been funded mainly through equity and debt financings, including PIPE proceeds and related-party debt.
Kohdistuu: Liquidity and operating continuity
Biopharma companies must successfully navigate research, clinical, and regulatory milestones before monetization.
Kohdistuu: Future pipeline
The company recently completed a complex merger and recapitalization, which can create operational, legal, and reporting complexity.
Kohdistuu: Post-merger execution
Kirjanpito
Harkinnanvaraiset erätLiminatus was deemed the accounting acquirer, so the transaction was treated as a recapitalization rather than a traditional acquisition.
Vaikutus: Affects balance sheet presentation and comparability
The filing states that the net assets of Iris were recorded at fair value with no goodwill or other intangible assets.
Vaikutus: Reduces future impairment risk from acquired goodwill
The company has no revenue and relies on financing to fund operations, making liquidity judgments critical.
Vaikutus: Can influence investor perception and disclosure
These funding sources affect cash flow, leverage, and the equity structure after the merger.
Vaikutus: Impacts financing costs and dilution
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
MIRA Pharmaceuticals, Inc
MIRA · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Provectus Biopharmaceuticals, Inc.
PVCT · Pharmaceutical Preparations
Citius Pharmaceuticals, Inc.
CTXR · Pharmaceutical Preparations
Matinas BioPharma Holdings, Inc.
MTNB · Pharmaceutical Preparations
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Päivitetty: 28.4.2026